Could an iron scavenger slow ALS?
NCT ID NCT02164253
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether deferiprone, a drug that removes excess iron, could safely slow the progression of ALS. Researchers gave the drug to 23 adults with ALS for several months. The goal was to see if reducing iron buildup in the brain might protect nerve cells and delay worsening of symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- deferiprone (an iron-removing drug)
- What this could lead to
- If it works, this could point toward a treatment that slows ALS progression by reducing excess iron in the brain.
- What could go wrong
- This is a small, early-phase pilot study with only 23 participants, so results may not apply to all ALS patients. The drug also carries risks like low white blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Roger Salengro, CHRU de Lille
Lille, 59000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood markers may unlock early ALS detection — a study puts them to the test
- Brain implant aims to give voice to those trapped in silence
- Nasal spray aims to tame brain inflammation in ALS
- Robotic arm could help people with paralysis regain independence at home
- Experimental cell therapy tested in 3 ALS patients
- Gene therapy injection hopes to slow ALS